Cargando…
Preclinical validation of a potent γ-secretase modulator for Alzheimer’s disease prevention
A potent γ-secretase modulator (GSM) has been developed to circumvent problems associated with γ-secretase inhibitors (GSIs) and to potentially enable use in primary prevention of early-onset familial Alzheimer’s disease (EOFAD). Unlike GSIs, GSMs do not inhibit γ-secretase activity but rather allos...
Autores principales: | Rynearson, Kevin D., Ponnusamy, Moorthi, Prikhodko, Olga, Xie, Yuhuan, Zhang, Can, Nguyen, Phuong, Hug, Brenda, Sawa, Mariko, Becker, Ann, Spencer, Brian, Florio, Jazmin, Mante, Michael, Salehi, Bahar, Arias, Carlos, Galasko, Douglas, Head, Brian P., Johnson, Graham, Lin, Jiunn H., Duddy, Steven K., Rissman, Robert A., Mobley, William C., Thinakaran, Gopal, Tanzi, Rudolph E., Wagner, Steven L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931646/ https://www.ncbi.nlm.nih.gov/pubmed/33651103 http://dx.doi.org/10.1084/jem.20202560 |
Ejemplares similares
-
Pharmacological and Toxicological Properties of the Potent Oral γ-Secretase Modulator BPN-15606
por: Wagner, Steven L., et al.
Publicado: (2017) -
Soluble γ-Secretase Modulators Selectively Inhibit the Production of the 42-Amino Acid Amyloid β Peptide Variant and Augment the Production of Multiple Carboxy-Truncated Amyloid β Species
por: Wagner, Steven L., et al.
Publicado: (2014) -
A γ-Secretase Inhibitor, but Not a γ-Secretase Modulator, Induced Defects in BDNF Axonal Trafficking and Signaling: Evidence for a Role for APP
por: Weissmiller, April M., et al.
Publicado: (2015) -
Molecular imaging of Alzheimer’s disease–related gamma-secretase in mice and nonhuman primates
por: Xu, Yulong, et al.
Publicado: (2020) -
Biogenesis of γ-secretase early in the secretory pathway
por: Kim, Jinoh, et al.
Publicado: (2007)